» Articles » PMID: 15086570

CD158k/KIR3DL2 is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-up of Sezary Syndrome

Overview
Publisher Elsevier
Specialty Dermatology
Date 2004 Apr 17
PMID 15086570
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

CD158k molecules belong to the family of killer cell immunoglobulin-like receptors (KIR) that are expressed on a minor population of circulating NK and CD8+ T lymphocytes. Here, we report a strong positive correlation between the percentage of CD158k+ blood lymphocytes analyzed by flow cytometry and the percentage of atypical circulating cells (Sezary cells) determined by cytomorphology in a large group of patients with Sezary syndrome. Moreover, we show that circulating CD4+CD158k+ lymphocytes correspond to the malignant clonal cell population. Our findings suggest that the CD158k marker could be a useful tool for the evaluation of the circulating tumoral burden and the follow-up of patients with Sezary syndrome.

Citing Articles

Sézary syndrome mimicking Steven-Johnson syndrome: A case report.

Fan S, Lai K Medicine (Baltimore). 2025; 103(52):e41080.

PMID: 39969314 PMC: 11687997. DOI: 10.1097/MD.0000000000041080.


mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy.

Knaneh J, Hodak E, Fedida-Metula S, Edri A, Eren R, Yoffe Y Cancers (Basel). 2023; 15(17).

PMID: 37686697 PMC: 10486495. DOI: 10.3390/cancers15174421.


Harnessing the immune system in the treatment of cutaneous T cell lymphomas.

Fay C, Awh K, LeBoeuf N, Larocca C Front Oncol. 2023; 12:1071171.

PMID: 36713518 PMC: 9878398. DOI: 10.3389/fonc.2022.1071171.


Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.

Hristov A, Tejasvi T, Wilcox R Am J Hematol. 2022; 98(1):193-209.

PMID: 36226409 PMC: 9772153. DOI: 10.1002/ajh.26760.


Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach.

Vermeer M, Moins-Teisserenc H, Bagot M, Quaglino P, Whittaker S Br J Dermatol. 2022; 187(1):21-28.

PMID: 35157307 PMC: 9541328. DOI: 10.1111/bjd.21053.